Why the study?
This study was undertaken to investigate the efficacy of apixaban in preventing haemorrhagic complications during endovascular treatment of proximal lower extremity deep vein thromboses.
Does apixaban combined with venous stenting improve venous outflow and prevent haemorrhagic complications compared to rivaroxaban without stenting in patients with late-stage proximal deep vein thrombosis undergoing endovascular treatment?
Does apixaban combined with venous stenting improve venous outflow and prevent haemorrhagic complications compared to rivaroxaban without stenting in patients with late-stage proximal deep vein thrombosis undergoing endovascular treatment?
In patients with late-stage proximal DVT undergoing endovascular treatment, apixaban combined with venous stenting was associated with improved venous outflow and a similar rate of haemorrhagic complications compared to rivaroxaban without stenting.
Hypothesis-generating for apixaban plus stenting in late proximal DVT; prospective RCTs needed before practice change.
PURPOSE: This study was undertaken to investigate efficacy of apixaban in prevention of haemorrhagic complications during treatment of proximal thromboses of deep veins of the lower extremities using endovascular techniques. PATIENTS AND METHODS: We retrospectively studied the results of treating a total of 50 patients presenting with deep vein thromboses at late stages of the pathological process. The patients were subdivided into 2 statistically homogeneous groups. Group One was composed of 30 patients undergoing treatment consisting in a combination of catheter-guided thrombolysis with urokinase and percutaneous mechanical thrombectomy, with rivaroxaban used for prolonged anticoagulation therapy. Group Two comprised 20 patients subjected to similar endovascular treatment with additional venous stenting. Prolonged 6-month anticoagulation therapy was carried out with apixaban. The results of treatment were assessed after 12 months by means of control ultrasonographic and clinical examination in order to determine the degree of restoration of the lumen of deep veins and severity of venous outflow impairments. RESULTS: After 1 year, in Group One patients there was no evidence of impaired venous outflow in 40% of patients, with a mild degree revealed in 40%, moderate degree in 13.3%, and severe degree in 6.7% of patients. In Group Two patients, there were no symptoms of venous insufficiency in 83.4%, with a mild degree revealed in 16.6%. Neither moderate nor severe impairments of venous outflow were observed. In Group One, manifestations of haemorrhagic syndrome on the background of taking rivaroxaban were noted to occur in 10% of patients and in Group Two on the background of taking apixaban also in 10% of patients. CONCLUSION: The use of apixaban in patients with proximal thromboses of deep veins of lower limbs on the background of treatment by endovascular techniques proved effective and safe.
No takes yet. Share an insight, caveat, or question.
Суковатых et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: